IP Library Granted Patent US 9,823,251
Granted Patent B2
US 9,823,251 · App. 15/226,794 · Granted Nov 21, 2017

Anti-Uroplakin II antibodies systems and methods

Inventors: Weimin Qi (Martinez, CA); David Tacha (San Ramon, CA)
Assignee: Biocare Medical, LLC
G01N33/57492C07K16/28C07K16/3038C07K2317/20C07K2317/34C07K2317/56C07K2317/565G01N2333/705
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,823,251
App. No.
15/226,794
Granted
Nov 21, 2017
Kind
B2
Abstract

The present invention is related to the anti-Uroplakin II antibodies, kits, cocktails, and use of anti-Uroplakin II antibodies for detection of cancer.

Claims (24)

1. An isolated antibody or isolated antigen binding fragment thereof comprising: heavy chain variable region complementarity determining region (CDR) sequences consisting of SEQ ID NOs: 5, 6, and 7; and

light chain variable region CDR sequences consisting of SEQ ID NOs: 8, 9, and 10 or SEQ ID NOs: 11, 12, and 13,

wherein the antibody or antigen binding fragment thereof specifically binds to Uroplakin II comprising SEQ ID NO: 4.

2. The antibody according to claim 1 wherein said antibody comprises a monoclonal antibody.

3. The antibody according to claim 2 wherein said monoclonal antibody is selected from a group consisting of a mouse monoclonal antibody, a rabbit monoclonal antibody, a goat monoclonal antibody, a horse monoclonal antibody, a chicken monoclonal antibody, a humanized monoclonal antibody and a chimeric antibody, and any combination thereof.

4. The isolated antibody or isolated antigen binding fragment thereof of claim 1 , wherein the isolated antibody or isolated antigen is conjugated with a label.

5. The antibody according to claim 4 wherein said label is selected from a group consisting of a radioactive element, magnetic particles, radioisotope, fluorescent dye, enzyme, toxin, signal, stain, detection enzymes, horseradish peroxidase (HRP), alkaline phosphatase (AP), beta-galactosidase, chromogens, Fast Red, 3,3′-diaminobenzidine, 3-amino-9-ethylcarbazole, 5-bromo-4-chloro-3-indolyl phosphate, 3,3′,5,5′-tetramethylbenzidine, 5-bromo-4-chloro-3-indolyl-β-D-glucuronide, and any combination thereof.

6. A composition comprising the isolated antibody or isolated antigen binding fragment thereof of claim 1 and at least one additional isolated antibody or isolated antigen binding fragment thereof, wherein the at least one additional isolated antibody or isolated antigen binding fragment thereof specifically binds to an antigen selected from the group consisting of GATA-3, p63, Uroplakin III, PAX8, NKX3.1, PSA and p40.

7. The composition according to claim 6 wherein said isolated antibody or isolated antigen binding fragment thereof and said at least one additional isolated antibody or isolated antigen binding fragment thereof each bind specifically to proteins selected from a group consisting of:

Uroplakin II and GATA-3;

Uroplakin II and p63;

Uroplakin II and Uroplakin III;

Uroplakin II and PAX8;

Uroplakin II and NKX3.1;

Uroplakin II and PSA;

Uroplakin II and Uroplakin III and GATA-3;

Uroplakin II and PAX8 and PSA;

Uroplakin II and PAX8 and NKX3.1; and

Uroplakin II and p40.

8. An immunoassay method for detecting Uroplakin II in a biological sample comprising:

(a) contacting the biological sample with the isolated antibody or isolated antigen binding fragment thereof of claim 1 wherein the antibody or antigen fragment thereof specifically binds Uroplakin II comprising SEQ ID NO: 4 to form a complex; and

(b) detecting the complex,

wherein the immunoassay is selected from the group consisting of immunohistochemistry (IHC), IHC of FFPE, IHC of frozen-tissue sections, immunocytochemistry and ELISA.

9. The method according to claim 8 wherein said biological sample is selected from a group consisting of blood, urine, urothelial tissue, transitional cell tissue, normal tissue, neoplastic tissue, bladder tissue, kidney tissue, ovarian tissue, thyroid tissue, endometrial tissue, renal tissue, tonsil tissue, pancreas tissue, colon tissue, lymph node tissue, stomach tissue, prostate tissue, lung tissue and breast tissue.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jun 25, 2026
From: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
To: BIOCARE MEDICAL LLC
Reel/Frame 075082/0723 →
SECURITY INTEREST Recorded Dec 9, 2021
From: BIOCARE MEDICAL LLC
To: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 058344/0799 →
RELEASE OF SECURITY INTEREST Recorded Dec 9, 2021
From: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
To: BIOCARE MEDICAL LLC
Reel/Frame 058351/0058 →
SECURITY INTEREST Recorded Aug 25, 2017
From: BIOCARE MEDICAL LLC
To: VARAGON CAPITAL PARTNERS AGENT, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 043401/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2016
From: QI, WEIMIN; TACHA, DAVID
To: BIOCARE MEDICAL, LLC
Reel/Frame 039398/0759 →
Continuity (3)
Continuation 14432132
Provisional Application 61706312 · Sep 27, 2012
Related Publication 20160334407A1 · Nov 17, 2016